Description

LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1].—Neuroscience-Neuromodulation–C30H57N7O8S—Biomed Pharmacother. 2023 Mar;159:114173.|Inflamm Res. 2022 Jul 28.|J Neurochem. 2022 Mar;160(6):662-674.-[1]Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.–533902-29-3–675.88—-CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CS)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O–Cardiovascular Disease–10 mM in DMSO–Others—-Others–Peptides